Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2859-2865

  Morrone, Luigi Francesco ^a   Mazzaferro, Sandro ^b   Russo, Domenico ^c   Aucella, Filippo ^d   Cozzolino, Mario ^e   Facchini, Maria Grazia ^f   Galfr, Andrea ^g   Malberti, Fabio ^h   Mereu, Maria Cristina ^d   Nordio, Maurizio ^d   Pertosa, Giovanni ⁱ   Santoro, Domenico ^j  

^a Renal Division   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Renal Division   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g Renal Division   (Italy)

^h CREMONA HOSPITAL   (Italy)

ⁱ POLICLINICO   (Italy)

^j UNIVERSITY OF MESSINA   (Italy)

more..

Author keywords

Charlson index; Elderly; Incident ESRD patients; Intact parathyroid hormone; Survival

Indexed keywords

CALCITRIOL; CALCIUM SALT; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D;

ADULT; ADVERSE OUTCOME; AGED; AGING; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HORMONE METABOLISM; HUMAN; HUMAN TISSUE; ITALY; KIDNEY BIOPSY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RENAL DIALYSIS; YOUNG ADULT;

EID: 69249089656     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp170     Document Type: Article

References (25)

1. Farrington K, Rao R, Gilg J et al. New adult patients starting renal replacement therapy in the UK in 2005 (Chapter 3). Nephrol Dial Transplant 2007; 22(Suppl 7): vii; 11-29
2. Misra M. Dialysis in the elderly. Blood Purif 2008; 26: 41-44
3. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol2007; 18: 2644-2648
4. Tomson C, Udayaraj U, Gilg J et al. Comorbidities in UK patients at the start of renal replacement therapy (Chapter 6). Nephrol Dial Transplant 2007; 22(Suppl 7): vii;58-68
5. Cruz JM, Piera L, Bragg-Gresham JL et al. Results of the international hemodialysis study DOPPS in Spain and Europe. Nefrologia 2003; 23: 437-443
6. Stel VS, van Dijk PC, van Manen JG et al. Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation. Nephrol Dial Transplant 2005; 20: 2803- 2811
7. Khan IH. Comorbidity: the major challenge for survival and quality of life in end-stage renal disease. Nephrol Dial Transplant 1998; 13(Suppl 1): 76-79
8. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidities in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
9. Hemmelgarn BR, Manns BJ, Quan H et al. Adapting the Charlson comorbidity index for use in patients with ESRD. Am J Kidney Dis2003; 42: 125-132
10. Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 337-342
11. Di Iorio B, Cillo N, Cirillo M et al. Charlson comorbidity index is a predictor of outcomes in incident hemodialysis patients and correlates with phase angle and hospitalization. Int J ArtifOrgans 2004; 27: 330- 336
12. Miskulin DC,Martin AA, Brown R et al. Predicting 1 year mortality in an outpatient hemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant 2004; 19: 413-420
13. Rustad P, Felding P, Franzson L et al. The Nordic reference interval project 2000: recommended reference intervals for 25 common biochemical properties. Scan J Clin Lab Invest 2004; 64: 271-284
14. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572
15. Kinchen KS, Sadler J, Fink N et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002; 137: 479-486
16. Greenland S. Principles of multilevelmodelling. Int J Epidemiol 2000; 29: 158-167
17. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
18. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol2004; 15: 2208-2218
19. Kalantar-Zadeh K,KuwaeN, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
20. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351- 357
21. Avram MM, Mittman N, Myint MM et al. Importance of low serum intact parathyroid hormone as a predictor ofmortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-1357
22. Bonne JF, Shahapuni I, Massy Z et al. Letter on the relation between serum Ca, PO4, and PTH with mortality in dialysis patients. Kidney Int 2007; 71: 178
23. Wald R, Sarnak MJ, Tighiouart H et al. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 2008; 52: 531-540
24. Johansen KL, Chertow GM. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients. J Ren Nutr 2007; 17: 305-313
25. Barreto FC,BarretoDV,Moys'esRMet al.K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73: 771-777